Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

The New England Journal of Medicine
Faiez ZannadCOMMANDER HF Investigators

Abstract

Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with worsening chronic heart failure and underlying coronary artery disease. In this double-blind, randomized trial, 5022 patients who had chronic heart failure, a left ventricular ejection fraction of 40% or less, coronary artery disease, and elevated plasma concentrations of natriuretic peptides and who did not have atrial fibrillation were randomly assigned to receive rivaroxaban at a dose of 2.5 mg twice daily or placebo in addition to standard care after treatment for an episode of worsening heart failure. The primary efficacy outcome was the composite of death from any cause, myocardial infarction, or stroke. The principal safety outcome was fatal bleeding or bleeding into a critical space with a potential for causing permanent disability. Over a median follow-up period of 21.1 months, the primary end point occurred in 626 (25.0%) of 2507 patients assigned to rivaroxaban and in 658 (26.2%) of 2515 patients assigned to placebo (hazard ratio, 0.94; 95% confidence interval [CI], 0.84...Continue Reading

References

Apr 3, 1998·Journal of the American College of Cardiology·A S Al-KhadraM A Konstam
Jun 2, 2006·European Journal of Heart Failure·Dennis V CokkinosUNKNOWN HELAS investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Nov 7, 2007·The New England Journal of Medicine·John KjekshusUNKNOWN CORONA Group
Feb 21, 2009·Cardiovascular Research·Julian Ilcheff BorissoffHugo ten Cate
Sep 3, 2009·The New England Journal of Medicine·Arthur J MossUNKNOWN MADIT-CRT Trial Investigators
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Dec 18, 2010·Nature Reviews. Drug Discovery·Elisabeth PerzbornFrank Misselwitz
Jul 8, 2011·The New England Journal of Medicine·C M O'ConnorR M Califf
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
May 4, 2012·The New England Journal of Medicine·Shunichi HommaUNKNOWN WARCEF Investigators
Mar 13, 2013·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN ASTRONAUT Investigators and Coordinators
Mar 30, 2013·European Journal of Heart Failure·Aldo P MaggioniUNKNOWN Heart Failure Association of the European Society of Cardiology (HFA)
Apr 14, 2017·The New England Journal of Medicine·Milton PackerUNKNOWN TRUE-AHF Investigators
Aug 29, 2017·The New England Journal of Medicine·John W EikelboomUNKNOWN COMPASS Investigators

❮ Previous
Next ❯

Citations

Jan 3, 2019·European Heart Journal·Petr WidimskyThomas F Lüscher
Feb 20, 2019·European Heart Journal·John G F ClelandPiotr Ponikowski
Mar 15, 2019·Journal of Atherosclerosis and Thrombosis·Jingyi LiuYasushi Sakata
Feb 23, 2019·Current Opinion in Nephrology and Hypertension·Jeffrey T HaMin Jun
Apr 21, 2019·European Heart Journal·Julian FriebelUrsula Rauch
Apr 25, 2019·JAMA Cardiology·Marvin A Konstam
May 24, 2019·Circulation Research·Islam Y ElgendyCarl J Pepine
Jun 4, 2019·Stroke; a Journal of Cerebral Circulation·Tiberiu A PanaPhyo K Myint
Aug 5, 2019·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Emanuele BertagliaPaulus Kirchhof
Aug 17, 2019·European Journal of Heart Failure·Jasper TrompCarolyn S P Lam
Jul 17, 2019·European Journal of Heart Failure·John J V McMurrayUNKNOWN DAPA-HF Committees and Investigators
Aug 10, 2019·Journal of Cardiovascular Medicine·Edoardo SciattiCarlo Mario Lombardi
Jan 29, 2020·Heart·Adam J Nelson, Manesh R Patel
Jul 30, 2019·Journal of Cardiovascular Pharmacology·Yuhu HeShenghua Zhou
May 5, 2020·European Journal of Heart Failure·Pooja DewanJohn J V McMurray
Dec 11, 2019·European Heart Journal·Morten Schou, Lars Køber
Jul 2, 2020·European Journal of Preventive Cardiology·Karsten KellerPhilip Wenzel
May 22, 2020·Expert Review of Clinical Pharmacology·José R González-JuanateyCarmen Suarez Fernández
Jun 28, 2019·Heart Asia·Tiberiu A PanaPhyo K Myint
Apr 30, 2019·Heart Asia·Zaid AlmarzooqMandeep R Mehra
Sep 9, 2018·Nature Reviews. Cardiology·Gregory B Lim
Aug 15, 2019·European Journal of Preventive Cardiology·Giulia RendaArtur Fedorowski
Nov 21, 2019·European Journal of Heart Failure·Jasper Tromp, Sean P Collins
Dec 11, 2019·European Journal of Heart Failure·Burkert PieskeUNKNOWN VICTORIA Study Group
Nov 24, 2019·Scientific Reports·Nathaniel R SmilowitzJeffrey S Berger
Jun 4, 2020·Continuum : Lifelong Learning in Neurology·Natalie R Weathered

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.